drugset / Trial / NCT04454476

Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor

NCT04454476

Phase 1 Active not recruiting 15 enrolled Vanderbilt-Ingram Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

This is a study of the safety and effectiveness of Trametinib treatment in patients who have received successful endoscopic submucosal resection of a Stage I gastric cancer.

Timeline

Start
2022-11-09
Primary completion
2024-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Trametinib Small molecule 1 mg Oral